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Introduction: The Runt-related transcription factor Runx2 is critical for skeletal development but is also aberrantly
expressed in breast cancers, and promotes cell growth and invasion. A de-regulated serine/threonine kinase Akt
signaling pathway is implicated in mammary carcinogenesis and cell survival; however, the mechanisms underlying
Runx2 role in survival of invasive breast cancer cells are still unclear.
Methods: The phenotypic analysis of Runx2 function in cell survival was performed by gene silencing and flow
cytometric analysis in highly invasive MDA-MB-231 and SUM-159-PT mammary epithelial cell lines. The expression
analysis of Runx2 and pAkt (serine 473) proteins in metastatic breast cancer specimens was performed by
immunohistochemistry. The mRNA and protein levels of kinases and phosphatases functional in Akt signaling
were determined by real-time PCR and Western blotting, while DNA-protein interaction was studied by chromatin
immunoprecipitation assays.
Results: The high Runx2 levels in invasive mammary epithelial cell lines promoted cell survival in Akt phosphorylation
(pAkt-serine 473) dependent manner. The analysis of kinases and phosphatases associated with pAkt regulation
revealed that Runx2 promotes pAkt levels via mammalian target of rapamycin complex-2 (mTORC2). The recruitment
of Runx2 on mTOR promoter coupled with Runx2-dependent expression of mTORC2 component Rictor defined Runx2
function in pAkt-mediated survival of invasive breast cancer cells.
Conclusions: Our results identified a novel mechanism of Runx2 regulatory crosstalk in Akt signaling that could have
important consequences in targeting invasive breast cancer-associated cell survival.Introduction
Breast cancer is the most commonly diagnosed form of
cancer and a serious health concern for women world-
wide [1]. One signaling mechanism that regulates breast
cancer cell survival and is widely used to develop drug
targets is the phosphatidyl inositol 3′ kinase (PI3K)-Akt
pathway [2]. However, results from recent pre-clinical
and clinical studies indicate a modest benefit from PI3K-
Akt inhibitors as breast cancer cells acquire resistance
due to feedback mechanisms and activation of other
oncogenic signaling pathways [2,3]. Therefore, under-
standing the molecular basis of signaling crosstalk op-
erative in cancer cells is required to improve the existing
therapies and find novel strategies to control invasive
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reproduction in any medium, provided the orThe Runt-related transcription factor, Runx2, is a key
regulator of normal bone development, homeostasis and
remodeling [4]; however, Runx2 is also aberrantly expressed
in several cancer types, including breast [5,6], prostate [7],
lung [8], ovarian [9] and osteosarcoma [10,11]. The Runx2
protein comprises structural motifs, including a DNA bind-
ing domain, nuclear localization signal (NLS) and nuclear
matrix targeting signal (NMTS), for the localization of the
protein into the nucleus [12]. The interaction of C-terminal
domain of Runx2 with co-activators or co-repressors
modulates downstream gene transcription in a context-
dependent manner [13].
The invasive breast cancer-derived MDA-MB-231 cells
express increased levels of Runx2 compared to non-
tumorigenic MCF-10A cells [5]. The Runx2 overexpres-
sion in MCF-10A cells disrupts the acinar structures in
three dimensional (3D) cultures and in poorly invasive
MCF-7 cells induces epithelium to mesenchymal transi-
tion [14]. The Runx2 and its co-activator CBF-β regulatesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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(MMP9 and MMP13), osteocalcin, bone sialoprotein and
genes related to cancer cell migration and invasion
[15-20]. These data highlight the invasive functions of
Runx2 in breast cancers.
In response to epidermal growth factor (EGF) stimula-
tion, the PI3K signaling pathway is activated, resulting in
phosphorylation of serine/threonine kinase Akt (pAkt).
The phosphorylation of Akt at Serine 473 residue is reg-
ulated by mammalian target of rapamycin complex-2
(mTORC2) and at Threonine 308 residue by phosphoi-
nositide dependent kinase-1 (PDK1) [21,22]. The activity
of mTORC2 complex depends on phosphorylation levels
of mTOR at Serine 2448 and 2481 residues, and levels
of Rictor and GβL proteins, while the mTORC1 complex
includes Raptor instead of Rictor protein. The activation
of Akt regulates downstream molecules (for example,
MDM2, FOXO and GSK-3β) resulting in enhanced cell
survival, proliferation and metabolism [23]. However, the
effect of crosstalk of Runx2 and PI3K/Akt signaling for
survival of breast cancer cells is still unknown.
In this study, we find that Runx2 suppression robustly
enhances apoptotic cell death in invasive cancer cell lines
in response to glucose- and growth factor-deprivation.
We show that Runx2 is required for maintaining pAkt
(Serine 473) levels in invasive mammary epithelial cell
lines via mTORC2 complex proteins. Altogether, our
results identify a novel mechanism implicating Runx2
regulatory network in the Akt cell survival pathway.
Methods
Cell culture, vectors and antibodies
All cell lines (ATCC, Manassas, VA, USA) were cultured
at 37°C in humidified incubator with 5% CO2. For rou-
tine cell culture, the human MCF-10A cells (ER-, PR-,
Her2+, WT-p53) [24] were cultured in Dulbecco's modified
Eagle's medium (DMEM)/F12 media (Cellgro, Mediatech,
Manassas, VA, USA) supplemented with 5% horse serum
(Lonza, Walkersville, MD, USA), insulin (10 μg/ml) (USP
Inc., Rockville, MD, USA), epidermal growth factor (EGF)
(20 ng/ml) (BD Biosciences, Bedford, MA, USA), cholera
toxin (100 ng/ml) (EMD Chemicals, Gibbstown, NJ, USA)
and hydrocortisone (0.5 ug/ml) (MP Biomedical, Santa
Ana, CA, USA), and 50 U/ml penicillin and 50 μg/ml
streptomycin (pen-strep) (Cellgro, Mediatech). The human
MCF-7 (ER+, PR +Her2+ WT-p53) [24] and MDA-MB-
231 (ER-, PR-, Her2-, mutant-p53) [24] cells were cultured
in MEM media (Cellgro, Mediatech) supplemented with
10% fetal bovine serum (FBS) (Cellgro, Mediatech) and
pen-strep. The SUM-159 and SUM-159-PT (ER-, PR-,
Her2-, mutant p53) [24] were cultured in F12 media (Life
Sciences Technology, Grand Island, NY, USA) supple-
mented with 5% FBS, HEPES (10 mM), Insulin (5 μg/ml),
hydrocortisone (1 μg/ml) and pen-strep. Since the celllines used in this study were commercially obtained, the
experiments performed in this study did not require
approval from our institution’s ethics committee.
For EGF treatment, the cells were deprived of serum
(final 0.25% serum) and growth factors, where appropri-
ate, for 16 hours. The cells were then treated with EGF
(100 ng/ml) in serum-deprived media for multiple time
points (10 minutes to 6 hours). In experiments requiring
PI3K inhibitor LY294002 (Cayman Chemical, Ann Arbor,
MI, USA) treatment, the serum-deprived cells were pre-
treated with LY294002 for 10 minutes before treatment
with EGF or LY294002.
The mouse monoclonal antibody for Runx2 was obtained
from MBL International Corporation, Woburn, MA, USA.
The antibodies for pAkt (Serine 473 and Threonine 308),
Akt (total), Akt1, Akt2, pPdk1 (Serine 241), pmTOR
(Serine 2448 and 2481), mTOR (total), Rictor, Raptor, GβL,
pGSK-3β (Serine 9) and FOXO1 were purchased from Cell
Signaling Technology, Danvers, MA, USA. The antibodies
for β-Actin and Lamin A/C were purchased from Santa
Cruz Biotechnology, Santa Cruz, CA, USA.
Transfection, transduction and stable cell line generation
The siRNA transfections for transient gene knockdown
were carried out by using oligofectamine as per the
manufacturer’s guidelines (Invitrogen, Grand Island, NY,
USA). The following siRNA sequences were commer-
cially (Ambion, Grand Island, NY, USA) synthesized:
PHLPP1: (Sense) CCG UUG GAG UGA UGC ACA
ATT. (Antisense) UUG UGC AUC ACU CCA ACG
GCT; Runx2: (Sense) CUU GAU GAC UCU AAA CCU
ATT. (Antisense) UAG GUU UAG AGU CAU CAA GCT.
The stable cell lines were generated utilizing lentivirus
vectors. The lentivirus vectors expressing WT-Runx2,
pLVTHM (RNAi-control) and Runx2-shRNA (Runx2-
RNAi) were described and generated previously [5]. The
lentiviral vector used to express constitutively active vari-
ant of Akt (CA-Akt) was kindly provided by Dr. Michael
B. Johnson (Children’s Hospital of Philadelphia, PA, USA).
The CA-Akt is deficient in pleckstrin homology domain
(Δ4-129) and contains a Src myristoylation signal resulting
in constitutive activation [25]. The early passage (<10)
stable cells were utilized in the various assays. The adeno-
virus (Ad) vectors expressing green fluorescent protein
(GFP) and WT-Runx2 were generated and described
previously [26]. The lentivirus vector expressing Rictor
shRNA was obtained from Addgene (plasmid #1853)
(Cambridge, MA, USA) [27]. The doxycycline regulated
knockdown of Runx2 was performed utilizing pLV-tTR-
KRAB vector expressing the tetracycline repressor tTR-
KRAB [28]. The tTR-KRAB binds to tetO operator in the
absence of doxycycline to suppress shRNA, while in the
presence of doxycycline it cannot bind to tetO, thus per-
mitting the shRNA-mediated gene knockdown. The cells
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harboring tetO were transduced with lentivirus expressing
pLV-tTR-KRAB to generate doxycycline-induced Runx2
knockdown.
Immunohistochemistry
The immunohistochemistry procedure was performed
according to instructions in the Vectastain Elite ABC kit
(Vector Laboratories Inc., Burlingame, CA, USA) but with
some modifications. A human invasive carcinoma tissue
microarray was obtained from US Biomax, Inc.,
(#BR1007) Rockville, MD, USA. This part of the study
did not require approval from the Institutional Review
Board as the tissue microarray was commercially
sourced. Briefly, the standard histology procedures were
used to deparaffinize the microarray slide in xylene and
rehydrate it in graded ethanol series. The target retrieval
was carried out by boiling the sections in citrate buffer
(pH 6) (Thermo Scientific, Fremont, CA, USA) at 95°C
for 15 minutes. The endogenous peroxidase activity
was quenched by incubating slides in 3% hydrogen per-
oxide for 10 minutes. The blocking was performed with
normal blocking serum (Vector Laboratories) for 30 mi-
nutes. The sections were subsequently incubated with
control or anti-Runx2 or anti pAkt (Serine 473) antibody
overnight at 4°C. The next day the sections were incu-
bated in diluted biotinylated secondary antibody for 30 mi-
nutes at room temperature followed by 30-minute
incubation with Vectastain Elite ABC reagent. The sec-
tions were thoroughly rinsed in PBS-T (PBS supplemented
with 0.1% Tween-20) in between the above mentioned
steps. The sections were finally incubated in peroxid-
ase substrate solution to develop color, followed by
washing in water, counter staining with hematoxylin
(Vector Laboratories), clearing in xylene and cover-
slipping with Permount (Fisher Scientific, Pittsburgh,
PA, USA). The staining intensity for Runx2 and pAkt
(Serine 473) were graded semi-quantitatively from 0 to 3
grades (0 = negative, 1 = low, 2 =medium and 3 = high)
blindly by two investigators (MT and JP). The experiments
were repeated three times.
Western blotting
The whole cell lysates were prepared by washing cells in cold
PBS and subsequently lysing in sample buffer containing
Tris-Cl (62.5 mM, pH 6.8), SDS (2% w/v), DTT (50 mM),
glycerol (10%) and bromophenol blue (0.01% w/v). The nu-
clear lysates were prepared in direct lysis buffer as previously
described [5]. The whole cell and nuclear lysates were loaded
in SDS-Gel and transferred to PVDF membrane and blotting
was performed as previously described. The data were quan-
tified in Adobe Photoshop (San Jose, CA, USA) and ImageJ
software (NIH, Bathesda, MD, USA). All the experiments
were repeated at least three times.Real-time PCR
The real time PCR with SYBR chemistry was performed
as previously described [29]. The following human pri-
mer pairs were used. Runx2: (F) TGC CTG CCT GGG
GTC TGT A (R) CGG GCC CTC CCT GAA CTC T;
mTOR: (F) TCC GGC TGC TGT AGC TTA TTA (R)
CGA GCA TAT GCC AAA GCA CT; Rictor: (F) CTT
CGA GGA GGA CTA AAC AC (R) CTA CAT CAG
CTC GCA CAT AC; PHLPP1 (1): (F) CCT CAT CCG
CTT CTA TGC AGG (R) GCATCTTGCCTTTACGGA-
CAT; PHLPP1 (2): (F) GCC AGT GAA CCG ATG GAC
AA (R) GTC CCA CAT AGG ATG ACT TGG; GAPDH:
(F) ATG TTC GTC ATG GGT GTG AA (R) TGT GGT
CAT GAG TCC TTC CA; 28S: (F) GAA CTT TGA
AGG CCG AAG TG (R) ATC TGA ACC CGA CTC
CCT TT. All the experiments were repeated at least
three times.
Chromatin Immunoprecipitation (ChIP)
The ChIP was performed as previously described [29].
The TF Search database was used to locate conserved
Runx binding sites in mTOR promoter (−5,000 bases)
[30]. The following primer pairs spanning Runx2 and
mTOR promoter were used: Runx2: (F) GAA AGA
GCA AGG GGG AAA AG (R) TGG AGA GGC AGA
ATC ATG TG; mTOR promoter: (F) CAG TGG TGC
AGT GGT GAG AT (R) AGG CAG GTG GAT TGT
TTG AG. The experiment was repeated at least three
times.
Flow cytometry
The Annexin V and AAD staining was performed as per
the manufacturer’s guidelines (BD Biosciences). The cell
cycle analysis with propidium iodide staining was per-
formed as previously described [31]. Briefly, the cells
were harvested after trypsinization and fixed in ethanol
for 24 hours in the cold. The fixed cells were washed in
PBS supplemented with 2% FBS and suspended in PBS
supplemented with RNAse (8 μg/ml) (Sigma-Aldrich, St.
Louis, MO, USA) and stained with propidium iodide
(18 μg/ml) (Invitrogen) for one hour. The cell cycle ana-
lysis was performed in FACS Canto (BD Biosciences).
The gating and data analysis were performed in FlowJo
software (Tree Star Inc., Ashland, OR, USA). The Dean
Jett Fox model was used to set gates for G1, S and G2
stage cells, while Sub-G1 was manually gated before G1
population. The experiments were repeated three times.
Cell proliferation
An indirect cell proliferation assay (Promega, Madison,
WI, USA) was used to estimate cell number in triplicates
at various time points in 96-well culture plates as previ-
ously described [29]. The media were supplemented with
formazan dye and incubated for one hour. The absorbance
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periments were repeated three times.
Results
Runx2-depleted MDA-MB-231 and SUM-159-PT cells
show increased apoptotic cell death with glucose- and
serum-deprivation
The invasive breast cancer cell lines and clinical speci-
mens express high levels of Runx2 compared to non-
tumorigenic breast epithelial MCF-10A cells (Additional
file 1: Figures S1A, S1B, Additional file 2: Figure S2 and
[5,6,15]). To determine the function of high endogenous
Runx2, we suppressed Runx2 levels via lentiviral shRNA
delivery in MDA-MB-231 cells (Additional file 1: Figure
S1C) and performed cell proliferation and survival as-
says. The MDA-MB-231cells with Runx2 knockdown
did not show any marked changes in cell proliferation
compared to controls (Additional file 1: Figure S1E).
Interestingly, when cultured in glucose- and serum-
deprivation conditions, most pronounced changes were
observed in Runx2 knockdown MDA-MB-231 cells. These
cells became round and non-adherent within 24 hours
compared to control cells (Figure 1A), suggesting increased
cell death. The Runx2 knockdown cells revealed an in-
creased (50% compared to control) Annexin V (a marker
for early apoptosis) and AAD (marker for late apoptosis or
dead cells) staining, indicating induction of apoptosis and
loss of cell viability (Figure 1B). The transient Runx2
knockdown with a dsRNA targeting different regions in
Runx2 RNA also showed increased apoptotic cell death in
response to glucose- and serum-deprivation (Additional
file 1: Figure S1F). The cell cycle analysis of stable Runx2
knockdown cells revealed an over 35% increase in hypodip-
loid cells in Sub-G1 phase and a decline in G1 (from 19%
to 3%), S (from 16% to 7%) and G2 (from 4% to 1%) phase
compared to control (Figure 1C, D). The increase in Sub-
G1 phase in Runx2 knockdown cells was partially restored
by reconstituting the cell culture media with glutamine
and was completely restored by reconstituting the media
with 10% serum or 1,000 mg/l glucose (Figure 1E). We fur-
ther validated the effect of Runx2 knockdown on cell death
in another invasive breast cancer cell line, SUM-159-PT.
The serum-, growth factor- and glucose-deprivation of
SUM-159-PT cells with Runx2 knockdown (Additional
file 1: Figure S1D) showed an increase in Annexin V stain-
ing (85% compared to control) for apoptosis (Figure 1F).
The cell cycle analysis also revealed an over three-fold in-
crease in Sub-G1 population (Figure 1G, H). These results
suggest that Runx2 expression in invasive MDA-MB-231
and SUM-159-PT breast cancer cells protects from growth
factor- and glucose starvation-induced cell death.
The Runx2 knockdown MDA-MB-231 cells with
glucose- and serum- deprivation also showed an in-
crease in caspase-3 cleavage, a hallmark of apoptosis,at multiple times (10 minutes to 24 h) compared to
control cells as examined by Western blot analysis
(Figure 2A-C) further confirmed the induction of apop-
tosis. The increased casapase-3 cleavage in Runx2 knock-
down cells was rescued by reconstituting 10% serum,
glutamine or glucose in the culture media (Figure 2B, C).
Since Akt activity is essential for growth factor-induced
cell survival, stimulation of glucose consumption in trans-
formed cells [32] and high Runx2 expression associated
with pAkt (Serine 473) positive specimens of invasive can-
cers (Additional file 2: Figure S2C-F), we examined pAkt
(Serine 473) levels in Runx2 knockdown cells under
serum- and glucose-deprivation. A corresponding decline
in Akt phosphorylation (pAkt-Serine 473) was also ob-
served in the Runx2 knockdown cells (Figure 2A, B). In
order to investigate whether the effect of Runx2 depletion
on cell survival in serum- and glucose-deprived conditions
was mediated through pAkt, we over-expressed a consti-
tutively active form of Akt (CA-Akt) in MDA-MB-231
cells. The exogenous expression of CA-Akt showed a ro-
bust increase in pAkt (Serine 473) levels (Figure 2D) and
protected the Runx2 knockdown MDA-MB-231 cells
(more than 25% compared to Runx2 knockdown alone)
from serum- and glucose starvation-induced cell death
(Figure 2E, F). Altogether, these results indicate that
Runx2 activates Akt signaling and increases survival of
invasive breast cancer cells in serum- and glucose
starvation-induced cell death.
Runx2 promotes Akt phosphorylation in highly invasive
(MDA-MB-231) mammary epithelial cells
In order to determine the function of Runx2 in the Akt sig-
naling pathway, we examined levels of pAkt and its down-
stream genes in response to serum-deprivation and EGF
stimulation in MDA-MB-231 cells. The serum-deprived
control or Runx2 knockdown MDA-MB-231 cells when
stimulated with EGF showed a potent induction of pAkt
(Serine 473), a readout for the Akt signaling pathway activ-
ity (Additional file 3: Figure S3A, C). The Runx2 knock-
down MDA-MB-231 cells showed reduction in pAkt at
Serine 473 in response to EGF stimulation at multiple time
points (10 minutes to 6 hours) examined (Figure 3A, B). A
persistent decline in pAkt (Serine 473) was also observed
with Runx2 knockdown with various doses (50 to 400 ng/
ml) of EGF (Additional file 3: Figure S3A-D). We further
confirmed the decline in pAkt levels by transient Runx2
knockdown using siRNA targeting a different Runx2
sequence (Figure 3C) and doxycycline-induced Runx2
knockdown (Figure 3D). To determine if Runx2 alters
Akt activity, we assessed the phosphorylation of the
downstream Akt target gene GSK-3β, and found that
Runx2 suppression reduced the pGSK-3β (Serine 9)
levels (Figure 3E, F). Since the phosphorylation of












Figure 1 Runx2 suppression increases apoptosis of invasive cells with glucose- and growth factor-deprivation. A) The stable Runx2-RNAi
or control MDA-MB-231 cells were deprived of glucose and serum for 24 hours. The morphology of these cells examined in brightfield
microscope (10X) is shown. B) The Runx2 knockdown or control MDA-MB-231 cells were deprived of glucose and serum for 24 hours. The cells were
then stained for Annexin V and AAD by flow cytometry. A representative cell population is shown. C) The glucose- and serum-deprived cells were
examined for cell cycle by propidium iodide (PI) staining in flow cytometry. A histogram of representative cell cycle stages is shown. D) A
quantification of average (± standard deviation) sub-G1, G1, S and G2 stages is indicated for PI stained Runx2-RNAi or control cells. E) The
Runx2-RNAi or control MDA-MB-231 cells were placed in serum-, glutamine- and glucose-deprived medium or a medium substituted with glutamine
and indicated doses of glucose for 24 hours. The fixed and PI-stained cells were then examined for sub-G1 population by flow cytometry. The
percentage of sub-G1 cells in control or Runx2 knockdown cells is shown. F) The Runx2 knockdown SUM-159-PT or control cells were deprived of
glucose and serum for 24 hours. The cells were then stained for Annexin V and AAD by flow cytometry. A representative cell population is
shown. G) The glucose- and serum-deprived SUM-159-PT cells were collected and examined for cell cycle by PI staining in flow cytometry.
A histogram of representative cell cycle stages is shown. H) A quantification of average (± standard deviation) sub-G1 stage is indicated for PI
stained Runx2-RNAi or control cells. * indicates P-value <0.05 derived from unpaired Student’s t-test.









Figure 2 Runx2 suppression increases caspase 3 cleavage in invasive MDA-MB-231 cells in response to glucose-deprivation. A, B, C) The
Runx2-RNAi or control MDA-MB-231 cells were deprived of glucose and serum for three hours. The cells were then left untreated or treated with 10%
serum for 10 minutes (A). The cells were then substituted with glutamine for 1 hour (B), and indicated concentrations of glucose for 24 hours (C). The
whole cell lysates were examined for cleaved caspase-3, pAkt and total Akt expression, while Lamin A/C protein levels served as the loading control in
Western blotting. D) The Runx2 knockdown or control MDA-MB-231 cells were utilized to re-express a constitutively active form of Akt (CA-Akt) or
matching green fluorescent protein (GFP) vector control. The whole cell lysates were analyzed for Akt exogenous CA-Akt over-expression. E) The control
or Runx2 knockdown MDA-MB-231 cells expressing CA-Akt or GFP were deprived of serum and glucose for 24 hours. The fixed cells were analyzed for
sub-G1 population. F) The mean ± standard deviation of percent sub-G1 cells is shown. * indicates P-value <0.05 derived from unpaired Student’s t-test.
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Figure 3 (See legend on next page.)
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Figure 3 Runx2 maintains pAkt levels in invasive MDA-MB-231 cells. A) The MDA-MB-231 cells stably expressing Runx2-RNAi or control were
serum-deprived and stimulated with epidermal growth factor (EGF) (100 ng/ml). The whole cell lysates were analyzed for pAkt (Serine 473) and
total Akt expression by Western blotting at indicated times. B) The average (± standard deviation) of normalized relative pAkt levels post EGF
stimulation at indicated time points are shown (*P <0.05). C) The MDA-MB-231 cells were transfected with dsRNA to transiently knockdown Runx2
gene expression. The serum-deprived cells were stimulated with EGF and pAkt (Serine 473) level was analyzed. D) The Runx2 gene expression
was conditionally suppressed by doxycycline in tTR-KRAB expressing MDA-MB-231 cells. The serum-deprived cells were stimulated with EGF and
pAkt (Serine 473) level was analyzed. E) The stable Runx2 knockdown MDA-MB-231 cells were examined for pAkt (Serine 473) and pGSK-3β
(Serine 9) expression by Western blotting. F) The pGSK-3β (Serine 9) expression was quantified from three blots and normalized expression level
is shown. G and H) The stable (G) or conditional (H) Runx2 knockdown MDA-MB-231 cells were stimulated with EGF at indicated times. The whole
cell lysates were examined for the expression of FOXO1 protein, while β-Actin was used as loading control. I) The WT-Runx2 (mouse) was
re-expressed by Ad vectors at indicated multiplicity of infection (MOI) in Runx2-RNAi MDA-MB-231 cells. The whole cell lysates of serum-deprived
and EGF treated cells were analyzed for pAkt (Serine 473) and the total Akt protein expression by Western blotting. The re-expression of mouse
WT-Runx2 was also confirmed. J) The control or Runx2 knockdown MDA-MB-231 cells were utilized to re-express WT-Runx2 (mouse) or green
fluorescent protein (GFP) via Ad vectors and were deprived of serum and glucose for 24 hours. The fixed cells were analyzed for sub-G1
population. A representative cell cycle profile is shown.
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with Runx2 suppression should result in increased
FOXO1 levels. As expected, the Runx2 knockdown in-
creased FOXO1 levels in the whole cell lysates stimu-
lated with EGF (Figure 3G, H). The basal expression levels
of Akt isoforms (Akt1 and Akt2), pAkt (Threonine 308)





Figure 4 Runx2 specifically maintains pAkt in invasive mammary epit
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To further establish the specificity of Runx2-mediated
pAkt regulation, we re-expressed WT-Runx2 in Runx2-
depleted MDA-MB-231 cells by Ad vectors. Although,
an activating effect of Ad vectors on pAkt is known
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Figure 5 Reducing PHLPP1 phosphatase and pERK kinase activity rescues Runx2-mediated inhibition of pAkt in MDA-MB-231 cells. A)
The PHLPP1 mRNA expression was transiently suppressed in MDA-MB-231 cells and gene expression was analyzed by real-time PCR. A quantification
of GAPDH normalized PHLPP1 mRNA expression is shown. B) A quantification of the relative phosphorylation levels of pAkt (Serine 473) were determined
by Western blotting in PHLPP1 knockdown MDA-MB-231 cells. C) The levels of pAkt (Serine 473) and total Akt proteins were analyzed by Western blot in
PHLPP1 knock out control or Runx2 suppressed MDA-MB-231 cells as indicated. A quantification of pAkt levels normalized to total Akt protein is shown
below the respective lane. D) The control or Runx2 knockdown MDA-MB-231 cells were stimulated with EGF for indicated times in the presence or
absence of ERK inhibitor U0126. The level of pAkt and Akt was determined by Western blotting and quantification is shown below the respective lane.
E) The Runx2 gene expression was conditionally suppressed by doxycycline in MDA-MB-231 cells stably expressing tTR-KRAB and Runx2-shRNA. The
serum-deprived cells were stimulated with EGF in the presence of ERK inhibitor PD184161 for indicated times. The pAkt and total Akt expression
was analyzed by Western blotting and a quantification of normalized expression is shown below the respective lanes.
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maintaining pAkt levels (Figure 3I). The restoration of
Runx2 expression was also sufficient to partially reduce the
sub-G1 population observed in MDA-MB-231 cells in re-
sponse to glucose- and serum-deprivation (Figure 3J).
These results indicate that Runx2 is required for maintain-
ing pAkt levels and survival of MDA-MB-231 cells.
Runx2-mediated increase in Akt phosphorylation is
specific for invasive cancer cells
To determine whether decreased pAkt (Serine 473) levels
with Runx2 suppression was specific for invasive cells, we
examined additional invasive cell lines (Hs578t, HCC-38,
SUM-159 and SUM-159-PT) with Runx2 knockdown and
response to EGF treatment. Of these cell lines tested,
SUM-159 and SUM-159-PT showed similar regulation as
observed in MDA-MB-231 cells. As these cell lines have
higher levels of endogenous pAkt (Serine 473) compared
to MDA-MB-231 cells (Figure 4A), we utilized selective
PI3K inhibitor, LY294002, to reduce basal pAkt levels. The
Runx2 knockdown in SUM-159 and SUM-159-PT cellsreduced pAkt (Serine 473) in EGF stimulated cells in the
presence of LY294002 (Figure 4B-E). As expected, because
of low levels of pAkt (Serine 473) in MDA-MB-231 cells,
treatment with LY294002 resulted in complete abrogation
of pAkt in both control and Runx2 knockdown cells
(Figure 4F). These results indicate that endogenous
Runx2 is required for maintaining pAkt levels in a sub-
set of invasive breast cancer cells.
In non-invasive (MCF7) and normal (MCF-10A) cells,
Runx2 knockdown (Additional file 4: Figure S4A, D)
showed no change in pAkt (Serine 473) in the absence
of LY294002 (Additional file 4: Figure S4B, E). Interest-
ingly, in the presence of LY294002, increased pAkt
(Serine 473) levels were detected (Additional file 4:
Figure S4B, E). A quantification of average pAkt (Serine
473) expression levels upon EGF stimulation at multiple
time points (one hour or less) in Runx2 knockdown
MCF-10A and MCF-7 cells is shown in Additional file 4:
Figure S4C, F. Taken together, these results show that
Runx2-mediated activation of Akt signaling is specific
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Figure 6 (See legend on next page.)
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Figure 6 Runx2 knockdown alters expression levels of mTORC-2 proteins. A) The MDA-MB-231 cells’ transient Runx2 suppression was analyzed
for mTOR and Runx2 levels. B) A quantification of mTOR protein expression normalized to β-Actin is shown. C) The stable Runx2 knockdown MDA-MB-231
cells were serum-deprived, epidermal growth factor (EGF) stimulated and examined for pmTOR (Serine 2481) and mTOR (total) protein. D) The Runx2
knockdown cells were assayed for mTOR gene expression by RT-PCR (normalized to GAPDH). E) The Runx2 knockdown and Ad-GFP- or
WT-Runx2-treated MDA-MB-231 cells were tested for Runx2 recruitment on mTOR promoter by ChIP assays. A schematic diagram of the
mTOR promoter region is bars indicating potential Runx binding sites (black bars) and location of PCR primers (small arrows). F) and G) The
mRNA (F) and protein (G) expression levels of Rictor were analyzed in control or Runx2 knockdown MDA-MB-231 cells by RT-PCR and Western
blotting, respectively. H) The MDA-MB-231 cells stably over-expressing WT-Runx2 were assayed for Runx2 and Rictor gene expression by RT-PCR. I) The
MDA-MB-231 cells with stable Rictor knockdown were stimulated with EGF and were analyzed for the expression of pAkt (Serine 473), Akt (total) and
Rictor protein levels by Western blotting. J) The stably Runx2 knockdown MDA-MB-231 cells together with Rictor suppression were stimulated with
EGF and analyzed for the expression of pAkt (Serine 473), Akt (total) and Rictor proteins by Western blotting. K) The glucose and serum-deprived (24 h)
MDA-MB-231 cells with Runx2 knockdown (Runx2-RNAi) together with Rictor knockdown (Rictor -shRNA) were stained for Annexin V and AAD by flow
cytometry. L) A quantification of positive cells with or without Rictor knockdown is shown.M) A schematic diagram depicting the function of Runx2 in
regulating Akt via mTORC2 complex and its effect on survival of invasive cancer cells.
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kinase activity restores pAkt levels in Runx2 knockdown
MDA-MB-231 cells
Several signaling events converge on the critical node of
Akt for cell survival [35]. We investigated the effect of
other regulators of pAkt on Runx2-mediated pAkt up-
regulation. First, we examined PHLPP1 phosphatase that
is known to dephosphorylate Akt (Serine 473) [36]. The
knockdown of PHLPP1 by siRNA in Runx2-depleted
MDA-MB-231 cells partially restored pAkt (Serine 473)
levels (Figure 5A-C). Secondly, a recent report indicated
ERK-mediated inhibition of pAkt [37], therefore, we ex-
amined pAkt levels upon pERK inhibition in Runx2
knockdown cells. The inhibition of pERK by U0126 par-
tially restored pAkt levels in Runx2 knockdown MDA-
MB-231 cells (Figure 5D). To confirm this result, we
used another specific pERK inhibitor, PD184161. The
ERK inhibition with PD184161 showed a completely re-
stored pAkt (Serine 473) levels in Runx2 knockdown
cells (Figure 5E). The difference in the extent of rescue
of pAkt (Serine 473) in Runx2 knockdown cells with
ERK kinase inhibitors U0126 or PD184161 could be due
to differences in the potencies of these two inhibitors.
The PD184161 has been reported to be more potent in
inhibiting phosphorylation of ERK1/2 than U0126 in hu-
man hepatocellular carcinoma cell lines [38]. These results
suggest that, although Runx2 could function in PHLPP1
or ERK independent manner, Runx2-dependent pAkt up-
regulation can be altered by inhibition of PHLPP1 or ERK
activity.
Runx2-mediated regulation of Akt phosphorylation is via
mTORC2 complex proteins in invasive MDA-MB-231 cells
To understand the underlying molecular mechanism of
Runx2-mediated up-regulation of pAkt in invasive MDA-
MB-231 cells, we determined the expression levels of the
mTORC2 subunit proteins, which are critical activators of
Akt phosphorylation at Serine 473 [22,27]. The transientor inducible Runx2 knockdown in MDA-MB-231 cells re-
duced the expression level of mTOR protein (Figure 6A-C
and Additional file 5: Figure S5A). The EGF treated Runx2
knockdown cells also showed reduction in phosphorylated
mTOR protein at 10 and 30 minutes (Figure 6C) and no
change at one hour (data not shown). The mRNA levels
were also reduced more than two-fold in Runx2 knock-
down cells compared to control cells (Figure 6D). In
addition to MDA-MB-231 cells, Runx2 knockdown in
SUM-159-PT cells also showed a decline in mTOR pro-
tein levels (Additional file 5: Figure S5B). To determine
whether mTOR gene expression was directly regulated by
Runx2, we examined binding of Runx2 on mTOR pro-
moter region (5 kb upstream from transcriptional start
site) by chromatin immunoprecipitation assays. Our result
showed a direct binding of Runx2 on the mTOR promoter
region (−2420 to −2441) containing two highly conserved
Runx binding elements at −2420 and −2430 bp spanning
22 base pairs (Figure 6E). The ChIP assays revealed that
endogenous and overexpressed Runx2 binds to mTOR
promoter and that this binding is reduced by Runx2
knockdown. The Runx2 promoter sequence was used as a
positive control as previously is shown that Runx2 binds
to its own promoter [39].
The expression of Rictor was also found to be reduced in
Runx2 knockdown MDA-MB-231 cells and SUM-159-PT
cell (Figure 6F, G and Additional file 5: Figure S5A, C, D).
The WT-Runx2 over-expression in MDA-MB-231 cells in-
creased Rictor expression, indicating that Rictor expression
is Runx2-dependent (Figure 6H). The expression of the
GβL subunit of the mTORC2 complex was minimally al-
tered with Runx2 knockdown (data not shown). To further
define the dependence of Runx2 on mTORC2 proteins in
regulating pAkt and cell survival, we suppressed Rictor ex-
pression in parental or Runx2 knockdown MDA-MB-231
cells. The Rictor suppression reduced (40 to 50%) pAkt
(Serine 473) levels compared to controls (Figure 6I),
whereas the combination of Runx2 and Rictor knockdown
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down in response to EGF stimulation in MDA-MB-231
cells (Figure 6J). Furthermore, Rictor suppression alone or
in combination with Runx2 robustly increased apoptotic
cell death under glucose- and growth factor-deprivation
compared to controls (Figure 6K, L). These results indi-
cate that Runx2 activates the Akt signaling pathway and
cell survival by regulating expression levels and activity of
mTORC2 complex in invasive breast cancer cells.
Discussion
The activated Akt signaling pathway, a common dysreg-
ulation in breast cancers, has been shown to promote
cancer cell growth, survival and metastasis [2,3]. We find
that Runx2 is required to maintain pAkt (Serine 473)
levels in a subset of invasive breast cancer cells. Further-
more, we show that Runx2 regulates Akt survival signal-
ing via mTOR and Rictor, key components of mTORC2
complex proteins. Interestingly, knockdown of Runx2
render these invasive cancer cells sensitive to apoptotic
cell death in response to glucose- and serum-deprivation.
Altogether, our findings indicate a novel Runx2 function
in cell survival by regulating Akt signaling in invasive
breast cancer cell lines (Figure 6M).
Previous studies have shown that functional mTORC2
complex is required for Akt phosphorylation at Serine
473 residue [27]. Consistent with this, our results show
that down-regulation of pAkt (Serine 473) in Runx2
knockdown MDA-MB-231 cells is associated with a de-
crease in mTOR and Rictor protein levels of mTORC2
complex. Furthermore, the knockdown of Rictor in
MDA-MB-231 cells reduced pAkt (Serine 473) levels
and enhanced apoptotic cell death under glucose- and
growth factor-deprivation. These results further support
the dependence of functional mTORC2 complex on
Runx2 in regulating pAkt levels. The binding of Runx2
on mTOR promoter could be influenced by recruitment
of Runx2 regulatory complex (chromatin remodelers such
as p300, CBP or HDACs) [19] or posttranslational modifi-
cations of Runx2 protein [40,41] further affecting basal ex-
pression levels and subsequent phosphorylation events of
mTOR protein. We did not observe changes in expression
levels of Raptor protein in MDA-MB-231 cells (data
not shown) upon Runx2 modulation suggesting that
mTORC1 is not involved in Runx2-mediated pAkt
signaling.
The differential Akt regulation by Runx2 in non-
invasive and invasive cancer cells could be due to altered
Runx2 phosphorylation in invasive cells. Several reports
indicate that in response to growth factor stimulation,
phosphorylation and DNA binding activity of Runx2 is
enhanced in osteogenic cell lines, endothelial cells and
osteosarcoma cell lines [42-44]. In normal cell types,
such as osteoblasts and chondrocytes, Runx2 DNAbinding and Akt activity is shown to be interdependent
during differentiation and cell migration of [42,45]. Inter-
estingly, it has been reported that Runx2 is directly phos-
phorylated by Akt that increases Runx2 DNA binding
activity in breast cancer cells (Figure 6M) [46]. Among
other signaling events converging on the critical node of
Akt [2,35], mutation of K-Ras (in MDA-MB-231 cells),
PI3KCA (in SUM-159 cells) and p53 can also contribute
to pAkt levels in invasive cell lines [24]. Higher endogen-
ous levels of Runx2 have been reported in p53 null osteo-
genic and osteosarcoma cancer cells [47,48]. The down-
regulation of p53 by Akt and inhibition of p53 transcrip-
tional activity by the Runx2-HDAC complex have also
been reported [2,35,47-50]. Based on these reports and
our data in p53, mutant MDA-MB-231 and SUM-159
cell lines suggest a crosstalk among Runx2, Akt and p53
pathways [19,40-42,45]. High levels of Runx2 have been
reported in breast cancers that correlated with clinical
stage, histological grade and Her2 status in clinical breast
cancer specimens [6]. Consistent with this report, our re-
sults show high levels of Runx2 and its association with
pAkt (Serine 473), suggesting activation of Akt signaling
in a subset of invasive cancers with high Runx2 expres-
sion. Our results in MDA-MB-231 cells indicate that
Runx2 alters FOXO1 levels, a downstream effector of
pAkt. Since FOXO1 has been shown to interact and in-
hibit the function of Runx2 in other cell types [51,52], it is
likely that Runx2 directly interacts with FOXO1 protein
as well as indirectly regulating its expression via modulat-
ing pAkt levels in mammary epithelial cells.
All three Runx transcription factors (Runx1, 2, 3) are
shown to be expressed at varying levels in mouse and
human normal or cancerous mammary epithelial cells
[53,54] and alterations in the levels of these factors dis-
rupt normal acinar structures of MCF-10A cells [5,55,56].
Consistent with the activation of PI3K/Akt signaling in
MCF-10A cells [55], our findings also show a temporal
regulation of EGF-induced pAkt levels by Runx2. Add-
itionally, Runx1 and Runx3 proteins have been shown
to regulate the PI3K/Akt pathway in megakaryocytic
leukemic and gastric cancer cell lines by directly affect-
ing expression levels of p110 and Akt1 proteins, re-
spectively [57,58]. Collectively, these findings suggest
that not only the relative levels of all three Runx pro-
teins are important but these proteins may also regu-
late multiple effectors of the PI3K/Akt pathway.
Our studies in MDA-MB-231 and SUM-159-PT cells
show that Runx2 knockdown increases cell death under
glucose and growth factor-deprivation-induced stress. It
has been shown in endothelial cells that glucose acti-
vates Runx2 phosphorylation, nuclear localization, DNA
binding and cell migration [59,60]. These findings indi-
cate that glucose metabolic signaling may synergize with
Runx2 regulation of the Akt pathway, affecting post-
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targets associated with cell survival. Taken together,
our findings show that Runx2 promotes cancer cell
survival by directly inducing subunits of mTORC2 kinase
complex of the Akt signaling pathway and further suggest
Runx2 inhibition as a potential therapeutic strategy in
combination with currently available PI3K/Akt/mTOR
inhibitors.
Conclusions
We have demonstrated that Runx2 is required for phos-
phorylation of Akt via directly regulating sub-units of the
mTORC2 complex. The Runx2-mediated pAkt regulation
promotes survival of invasive mammary epithelial cells.
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